Patents by Inventor Zhihong Li

Zhihong Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210230189
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: February 24, 2017
    Publication date: July 29, 2021
    Applicant: AMGEN INC.
    Inventors: Sean P. BROWN, David Karl BEDKE, Micheal R. DEGRAFFENREID, Jiasheng FU, Zhihong LI, Felix GONZALEZ LOPEZ TURISO, Ana GONZALEZ BUENROSTRO, Micheal W. GRIBBLE, JR., Micheal G. JOHNSON, Todd J. KOHN, Kexue LI, Yunxiao LI, Mike Elias LIZARZABURU, Yosup REW, Joshua TAYGERLY, Yingcal WANG, Xuelei YAN, Ming YU, Jiang ZHU, Manuel ZANCANELLA, Xian Yun JIAO, Liusheng ZHU, Xianghong WANG, Julio C. MEDINA, Jason A. DUQUETTE, Jonathan B. HOUZE, Marc VIMOLRATANA, Marlo G. CARDOZO, Alan C. CHENG
  • Publication number: 20210220353
    Abstract: The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.
    Type: Application
    Filed: October 14, 2020
    Publication date: July 22, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan CAO, Cheng CAO, Ting GAO, Gengfu XIAO, Zhihong HU, Manli WANG, Leike ZHANG, Song LI
  • Publication number: 20210220377
    Abstract: The present application relates to use of a substituted aminopropionate compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the compound for the treatment of a disease or an infection caused by a SARS-CoV-2.
    Type: Application
    Filed: October 14, 2020
    Publication date: July 22, 2021
    Applicant: Academy of Military Medical Sciences
    Inventors: Wu ZHONG, Ruiyuan Cao, Gengfu Xiao, Zhihong Hu, Manli Wang, Leike Zhang, Wei Li, Yuexiang Li, Lei Zhao, Shiyong Fan, Song Li
  • Publication number: 20210212853
    Abstract: A splint and a method for operating a splint are disclosed. The splint includes a plurality of plates, at least one rope, and at least one fastening drive device. The plurality of plates include a first plate. The rope is in movable connection with the plurality of plates. The fastening drive device is on the first plate, and is connected to the rope and configured to drive the rope under control, so as to allow the rope to be tightened or loosened under drive of the fastening drive device to drive the plurality of plates to move relatively close to each other or relatively away from each other.
    Type: Application
    Filed: November 13, 2019
    Publication date: July 15, 2021
    Inventors: Zhihong DU, Wenbo LI
  • Publication number: 20210179560
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: August 3, 2020
    Publication date: June 17, 2021
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, I, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua MA, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yossup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • Publication number: 20210147409
    Abstract: An 8-dihalomethyl berberine-type quaternary ammonium salt compound represented by general formula (I) or (II) and an application thereof in preparing a drug. The compound shows hydrophilicity and has antimicrobial, anti-inflammatory, anti-ulcerative colitis, and antitumor activities, while having no or low toxicity.
    Type: Application
    Filed: April 15, 2019
    Publication date: May 20, 2021
    Inventors: Hailin QIN, Lianqiu WU, Xiang LI, Haijing ZHANG, Li SONG, Huachen SONG, Anjun DENG, Xiaonan TANG, Zhihui ZHANG, Xiang LI, Zhihong LI
  • Publication number: 20210055230
    Abstract: A device and a method for simultaneously inspecting defects of a surface and a subsurface of an optical element are provided. Combined with laser-induced ultrasound and laser scattering inspection technologies, through generating acoustic sound waves on the surface and the subsurface of the optical element to be tested by lasers, a static light scattering effect of subsurface defects under modulation of the acoustic sound wave is observed and analyzed; through analyzing amplitude and phase changes of scattered light intensity and reflected light intensity, inspection for the defects of the surface and the subsurface of the optical element is realized. The present invention can be applied in quality inspection of precise optical elements, especially in finished product inspection of ultra-precise optical elements having strict requirements on the subsurface defects.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 25, 2021
    Inventors: Anyu Sun, Zhihong Li, Bingfeng Ju, Chuanyong Wang, Xiaoyu Yang, Zeqing Sun, Huilin Du
  • Patent number: 10836779
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: November 17, 2020
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Yunxiao Li, Mike Elias Lizarzaburu, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Ming Yu, Manuel Zancanella, Liusheng Zhu, Ana Gonzalez Buenrostro, Zhihong Li
  • Patent number: 10833508
    Abstract: An active power distribution network multi-time scale coordinated optimization scheduling method and storage medium are provided. The method includes the following steps: performing long-time scale optimization scheduling of an active power distribution network; performing short-time scale rolling optimization scheduling on the basis of MPC of the active power distribution network according to an optimization result of the long-time scale optimization scheduling of the active power distribution network. By using a model prediction control method, taking the long-time scale optimization scheduling result as a reference, and performing short-time scale rolling correction, the optimization scheduling of the active power distribution network is achieved, thereby reducing unfavorable influences of prediction precision of a distributed power supply and a low-voltage load on the optimization scheduling.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: November 10, 2020
    Assignees: CHINA ELECTRIC POWER RESEARCH INSTITUTE COMPANY LIMITED, STATE GRID CORPORATION OF CHINA, NORTH CHINA ELECTRIC POWER UNIVERSITY, STATE GRID BEIJING ELECTRIC POWER COMPANY, STATE GRID TIANJIN ELECTRIC POWER COMPANY
    Inventors: Xiaohui Wang, Tianjiao Pu, Lei Dong, Naishi Chen, Ye Li, Jiancheng Yu, Renle Huang, Xianjun Ge, Zhihong Li, Minghao Ai, Fumin Qu, Liqiang Zhao
  • Publication number: 20200316248
    Abstract: The present invention relates to an alkyl chitosan-graphene oxide composite sponge and preparation method and application thereof. The alkyl chitosan-graphene oxide composite sponge provided by the present invention includes alkyl chitosan and graphene oxide absorbed on the alkyl chitosan, and the adsorbing capacity of the graphene oxide is 3-28 wt. %. In the present invention, alkyl chitosan is used as a matrix to combine graphene oxide and alkyl chitosan; the obtained composite sponge has excellent hemostatic performance and blood absorption capacity. Results of embodiments indicate that the in-vitro whole blood coagulation time is less than 58 s, the hemostasis time of a rabbit femoral artery hemorrhage model is less than 155 s, the hemorrhage mass is less than 5.4 g, and the hemostatic effect is superior to a pure alkyl chitosan sponge or graphene oxide powder when the composite sponge provided by the present invention is used for hemostasis.
    Type: Application
    Filed: October 24, 2019
    Publication date: October 8, 2020
    Applicant: Institute of Medical Support Technology, Academy of System Engineering, Academy of Military Science
    Inventors: Jing GUAN, Jian YANG, Ying ZHANG, Feng TIAN, Jimin WU, Sheng DING, Zhihong LI, Chunlai WANG
  • Publication number: 20200079793
    Abstract: Disclosed herein, inter alia, are compositions and methods for modulating Adenosine Receptors.
    Type: Application
    Filed: August 30, 2019
    Publication date: March 12, 2020
    Inventors: Zhihong Li, Lubov Konstantinovna Filonova, Erik Verner
  • Publication number: 20200062780
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 13, 2019
    Publication date: February 27, 2020
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Publication number: 20200033933
    Abstract: An active power distribution network multi-time scale coordinated optimization scheduling method and storage medium are provided. The method includes the following steps: performing long-time scale optimization scheduling of an active power distribution network; performing short-time scale rolling optimization scheduling on the basis of MPC of the active power distribution network according to an optimization result of the long-time scale optimization scheduling of the active power distribution network. By using a model prediction control method, taking the long-time scale optimization scheduling result as a reference, and performing short-time scale rolling correction, the optimization scheduling of the active power distribution network is achieved, thereby reducing unfavorable influences of prediction precision of a distributed power supply and a low-voltage load on the optimization scheduling.
    Type: Application
    Filed: June 27, 2016
    Publication date: January 30, 2020
    Inventors: Xiaohui Wang, Tianjiao Pu, Lei Dong, Naishi Chen, Ye Li, Jiancheng Yu, Renle Huang, Xianjun Ge, Zhihong Li, Minghao Ai, Fumin Qu, Liqiang Zhao
  • Patent number: 10309021
    Abstract: The disclosure provides a method for preparing an electrolyte and an electrolyte replenishment system during an electrolytic process. The method includes the following steps: Step A: placing aluminum in a reactor, vacuumizing the reactor and feeding an inert gas, heating the reactor to 700-850 degrees centigrade, and adding one or more of potassium fluozirconate, potassium fluoborate, sodium hexafluorozirconate and sodium fluoroborate; and Step B: stirring the reactants for 4-6 hours and extracting the upper molten liquid to obtain an electrolyte replenishment system during an aluminum electrolysis process. The disclosure has the following beneficial effects: when used in the aluminum electrolysis industry, the electrolyte system provided herein can be directly used as an aluminum electrolyte or a replenishment system in an electrolyte without changing existing electrolysis technology to significantly reduce an electrolysis temperature during an aluminum electrolysis process.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: June 4, 2019
    Assignee: SHENZHEN SUNXING LIGHT ALLOYS MATERIALS CO., LTD.
    Inventors: Xuemin Chen, Jun Yang, Zhihong Li, Weiping Wu, Shiming Wei
  • Patent number: 10277354
    Abstract: An optical fiber system including an optical fiber and an optical grating is provided. The optical fiber is configured to support M mode groups, where differences in effective refractive index between adjacent mode groups are substantially equal. The optical grating is optically coupled to the optical fiber, and has a period inversely proportional to the difference in effective refractive index between adjacent mode groups. The optical grating is configured to couple all adjacent mode groups in the optical fiber.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: April 30, 2019
    Assignees: Futurewei Technologies, Inc., University of Central Florida Research Foundation, Inc.
    Inventors: Guifang Li, Zhihong Li, Demetrios Christodoulides, Huiyuang Liu, He Wen, Mohammadamin Eftekhar, Bin Huang
  • Publication number: 20190062276
    Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.
    Type: Application
    Filed: March 21, 2018
    Publication date: February 28, 2019
    Inventors: Michael D. Bartberger, Ana Gonzalez Buenrostro, Hilary Plake Beck, Xiaoqi Chen, Richard Victor Connors, Jeffrey Deignan, Jason A. Duquette, John Eksterowicz, Benjamin Fisher, Brian M. Fox, Jiasheng Fu, Zice Fu, Felix Gonzalez Lopez De Turiso, Michael W. Gribble, JR., Darin J. Gustin, Julie A. Heath, Xin Huang, XianYun Jiao, Michael G. Johnson, Frank Kayser, David John Kopecky, SuJen Lai, Yihong Li, Zhihong Li, Jiwen Liu, Jonathan D. Low, Brian S. Lucas, Zhihua Ma, Lawrence R. McGee, Joel McIntosh, Dustin L. McMinn, Julio C. Medina, Jeffrey Thomas Mihalic, Steven H. Olson, Yosup Rew, Philip M. Roveto, Daqing Sun, Xiaodong Wang, Yingcai Wang, Xuelei Yan, Ming Yu, Jiang Zhu
  • Patent number: 10202701
    Abstract: The invention provides a potassium cryolite for aluminum electrolysis industry, which has a molecular formula: mKF.AlF3, wherein m is from 1 to 1.5. The low-molecular-ratio potassium cryolite (mKF.AlF3, and m is from 1 to 1.5) provided by the invention is used for aluminum electrolysis industry, and can improve the dissolvability of aluminum oxide, thus reducing the temperature of electrolysis and the consumption of power, raising the efficiency of electrolysis and lowering the comprehensive production cost.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: February 12, 2019
    Assignee: SHENZHEN SUNXING LIGHT ALLOYS MATERIALS CO., LTD.
    Inventors: Xuemin Chen, Jun Yang, Zhihong Li, Weiping Wu
  • Publication number: 20190023720
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 24, 2019
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S, LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Publication number: 20190016736
    Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 6, 2018
    Publication date: January 17, 2019
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S. LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Patent number: 10100063
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: December 12, 2016
    Date of Patent: October 16, 2018
    Assignee: AMGEN INC.
    Inventors: Sean P. Brown, Yunxiao Li, Mike Elias Lizarzaburu, Brian S. Lucas, Nick A. Paras, Joshua Taygerly, Marc Vimolratana, Xianghong Wang, Ming Yu, Manuel Zancanella, Liusheng Zhu, Ana Gonzalez Buenrostro, Zhihong Li